The Concept of “Platinum Sensitivity” in Endometrial Cancer
Simple Summary
Abstract
1. Introduction
2. The Concept of Platinum Sensitivity in Recurrent Ovarian Cancer
3. The Concept of Platinum Sensitivity in Recurrent Endometrial Cancer
4. Another Aspect of the Concept of Platinum Sensitivity
5. Platinum Sensitivity in the Context of Recent Treatment Strategies
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
Abbreviations
ICI | Immune checkpoint inhibitor |
TC | Paclitaxel plus carboplatin (Taxol–Carbo) chemotherapy |
MMR | Mismatch repair |
dMMR | Deficient mismatch repair |
pMMR | Proficient mismatch repair |
PFI | Platinum-free interval |
TFI | Treatment-free interval |
PFS | Progression-free survival |
OS | Overall survival |
DSPR | Duration of secondary platinum response |
HR | Hazard ratio |
GOG | Gynecologic Oncology Group |
SGSG | Sankai Gynecologic Study Group |
GOTIC | Gynecologic Oncology Trial and Investigation Consortium |
NCCN | National Comprehensive Cancer Network |
ESGO | European Society of Gynaecological Oncology |
NSMP | No specific molecular profile |
MSI-H | Microsatellite instability-high |
LEN + PEM | Lenvatinib plus pembrolizumab |
References
- Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 2023, 73, 17–48. [Google Scholar] [CrossRef] [PubMed]
- Crosbie, E.J.; Kitson, S.; McAlpine, J.N.; Mukhopadhyay, A.; Powell, M.E.; Singh, N.; Temkin, S.M.; Gilks, C.B. Endometrial cancer. Lancet 2022, 399, 1412–1428. [Google Scholar] [CrossRef]
- Morice, P.; Leary, A.; Creutzberg, C.; Abu-Rustum, N.; Darai, E. Endometrial cancer. Lancet 2016, 387, 1094–1108. [Google Scholar] [CrossRef]
- Miller, D.S.; Filiaci, V.L.; Mannel, R.S.; Cohn, D.E.; Matsumoto, T.; Tewari, K.S.; DiSilvestro, P.A.; Pearl, M.L.; Argenta, P.A.; Powell, M.A.; et al. Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J. Clin. Oncol. 2020, 38, 3841–3850. [Google Scholar] [CrossRef] [PubMed]
- Makker, V.; Green, A.K.; Wenham, R.M.; Mutch, D.; Davidson, B.; Miller, D.S. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol. Oncol. 2021, 162, 3–13. [Google Scholar] [CrossRef] [PubMed]
- Cancer Genome Atlas Research Network; Kandoth, C.; Schultz, N.; Cherniack, A.D.; Akbani, R.; Liu, Y.; Shen, H.; Robertson, A.G.; Pashtan, I.; Shen, R.; et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497, 67–73. [Google Scholar] [CrossRef]
- O'Malley, D.M.; Bariani, G.M.; Cassier, P.A.; Marabelle, A.; Hausen, A.R.; Acosta, A.D.J.; Miller Jr, W.H.; Safra, T.; Italiano, A.; Mileshkin, L.; et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: Results from the KEYNOTE-158 study. J. Clin. Oncol. 2022, 40, 752–761. [Google Scholar] [CrossRef]
- Marabelle, A.; Le, D.T.; Ascierto, P.A.; Di Giacomo, A.M.; De Jesus-Acosta, A.; Delord, J.P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 2020, 38, 1–10. [Google Scholar] [CrossRef]
- Markman, M.; Rothman, R.; Hakes, T.; Reichman, B.; Hoskins, W.; Rubin, S.; Jones, W.; Almadrones, L.; Lewis, J.L. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 1991, 9, 389–393. [Google Scholar] [CrossRef]
- Stuart, G.C.; Kitchener, H.; Bacon, M.; duBois, A.; Friedlander, M.; Ledermann, J.; Marth, C.; Thigpen, T.; Trimble, E.; on behalf of participants of 4th Ovarian Cancer Consensus Conference (OCCC). 2010 Gynecologic Cancer Intergroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the Fourth Ovarian Cancer Consensus Conference. Int. J. Gynecol. Cancer 2011, 21, 750–755. [Google Scholar] [CrossRef]
- Friedlander, M.; Trimble, E.; Tinker, A.; Alberts, D.; Avall-Lundqvist, E.; Brady, M.; Harter, P.; Pignata, S.; Pujade-Lauraine, E.; Sehouli, J.; et al. Clinical trials in recurrent ovarian cancer. Int. J. Gynecol. Cancer 2011, 21, 771–775. [Google Scholar] [CrossRef]
- Pignata, S.; Cecere, S.C.; Du Bois, A.; Harter, P.; Heitz, F. Treatment of recurrent ovarian cancer. Ann. Oncol. 2017, 28 (Suppl. 8), viii51–viii56. [Google Scholar] [CrossRef]
- Lindemann, K.; Gao, B.; Mapagu, C.; Fereday, S.; Emmanuel, C.; Alsop, K.; Traficante, N.; Australian Ovarian Cancer Study Group; Harnett, P.R.; Bowtell, D.D.L.; et al. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol. Oncol. 2018, 150, 239–246. [Google Scholar] [CrossRef] [PubMed]
- McGee, J.; Bookman, M.; Harter, P.; Marth, C.; McNeish, I.; Moore, K.N.; Poveda, A.; Hilpert, F.; Hasegawa, K.; Bacon, M.; et al. Fifth Ovarian Cancer Consensus Conference: Individualized therapy and patient factors. Ann. Oncol. 2017, 28, 702–710. [Google Scholar] [CrossRef] [PubMed]
- Colombo, N.; Sessa, C.; du Bois, A.; Ledermann, J.; McCluggage, W.G.; McNeish, I.; Morice, P.; Pignata, S.; Ray-Coquard, I.; Vergote, I.; et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann. Oncol. 2019, 30, 672–705. [Google Scholar] [CrossRef]
- Moore, K.N.; Tian, C.; McMeekin, D.S.; Thigpen, J.T.; Randall, M.E.; Gallion, H.H. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? Cancer 2010, 116, 5407–5414. [Google Scholar] [CrossRef]
- Nagao, S.; Nishio, S.; Michimae, H.; Tanabe, H.; Okada, S.; Otsuki, T.; Tanioka, M.; Fujiwara, K.; Suzuki, M.; Kigawa, J. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study. Gynecol. Oncol. 2013, 131, 567–573. [Google Scholar] [CrossRef] [PubMed]
- Nagao, S.; Nishio, S.; Okada, S.; Otsuki, T.; Fujiwara, K.; Tanabe, H.; Takano, M.; Hasumi, Y.; Takei, Y.; Hasegawa, T.; et al. What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study. Cancer Chemother. Pharmacol. 2015, 76, 335–342. [Google Scholar] [CrossRef]
- Markman, M.; Markman, J.; Webster, K.; Zanotti, K.; Kulp, B.; Peterson, G.; Belinson, J. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design. J. Clin. Oncol. 2004, 22, 3120–3125. [Google Scholar] [CrossRef]
- Nagao, S.; Nishio, S.; Takehara, K.; Sato, S.; Satoh, T.; Shimada, M.; Yamaguchi, S.; Tanabe, H.; Takano, M.; Horie, K.; et al. Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: An ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study. Int. J. Clin. Oncol. 2024, 29, 1594–1601. [Google Scholar] [CrossRef]
- Yang, L.; Xie, H.; Li, Y.Y.; Wang, X.; Liu, X.; Zhang, X. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer. Oncol. Rep. 2022, 48, 199. [Google Scholar] [CrossRef] [PubMed]
- Havași, A.; Căinap, S.; Havasi, A.T.; Căinap, C. Ovarian cancer—Insights into platinum resistance and overcoming it. Medicina 2023, 59, 1017. [Google Scholar] [CrossRef] [PubMed]
- McMullen, M.; Madariaga, A.; Lheureux, S. New approaches for targeting platinum-resistant ovarian cancer. Semin. Cancer Biol. 2021, 77, 185–199. [Google Scholar] [CrossRef] [PubMed]
- Damia, G.; Broggini, M. Platinum resistance in ovarian cancer: Role of DNA repair. Cancers 2019, 11, 119. [Google Scholar] [CrossRef]
- McMullen, M.; Karakasis, K.; Madariaga, A.; Oza, A.M. Overcoming platinum and PARP-inhibitor resistance in ovarian cancer. Cancers 2020, 12, 1607. [Google Scholar] [CrossRef]
- van Zyl, B.; Tang, D.; Bowden, N.A. Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment. Endocr. Relat. Cancer 2018, 25, R303–R318. [Google Scholar] [CrossRef]
- Makker, V.; Colombo, N.; Casado Herráez, A.; Santin, A.D.; Colomba, E.; Miller, D.S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S.; Ray-Coquard, I.; et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N. Engl. J. Med. 2022, 386, 437–448. [Google Scholar] [CrossRef]
- Eskander, R.N.; Sill, M.W.; Beffa, L.; Moore, R.G.; Hope, J.M.; Musa, F.B.; Mannel, R.S.; Shahin, M.S.; Cantuaria, G.H.; Girda, E.; et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat. Med. 2025, 31, 1539–1546. [Google Scholar] [CrossRef]
- Westin, S.N.; Moore, K.; Chon, H.S.; Lee, J.Y.; Thomes Pepin, J.; Sundborg, M.; Shai, A.; de la Garza, J.; Nishio, S.; Gold, M.A.; et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J. Clin. Oncol. 2024, 42, 283–299. [Google Scholar] [CrossRef]
- Mirza, M.R.; Chase, D.M.; Slomovitz, B.M.; dePont Christensen, R.; Novák, Z.; Black, D.; Gilbert, L.; Sharma, S.; Valabrega, G.; Landrum, L.M.; et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N. Engl. J. Med. 2023, 388, 2145–2158. [Google Scholar] [CrossRef]
- Powell, M.A.; Bjørge, L.; Willmott, L.; Novák, Z.; Black, D.; Gilbert, L.; Sharma, S.; Valabrega, G.; Landrum, L.M.; Gropp-Meier, M.; et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann. Oncol. 2024, 35, 728–736. [Google Scholar] [CrossRef] [PubMed]
- Colombo, N.; Biagioli, E.; Harano, K.; Galli, F.; Hudson, E.; Antill, Y.; Choi, C.H.; Rabaglio, M.; Marmé, F.; Marth, C.; et al. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024, 25, 1135–1146. [Google Scholar] [CrossRef]
- Galant, N.; Krawczyk, P.; Monist, M.; Obara, A.; Gajek, Ł.; Grenda, A.; Nicoś, M.; Kalinka, E.; Milanowski, J. Molecular classification of endometrial cancer and its impact on therapy selection. Int. J. Mol. Sci. 2024, 25, 5893. [Google Scholar] [CrossRef] [PubMed]
- Marth, C.; Moore, R.G.; Bidziński, M.; Pignata, S.; Ayhan, A.; Rubio, M.J.; Beiner, M.; Hall, M.; Vulsteke, C.; Braicu, E.I.; et al. First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial. J. Clin. Oncol. 2025, 43, 1083–1100. [Google Scholar] [CrossRef] [PubMed]
re-administration [17] | ||||
Platinum-free interval (months) | ||||
PFI < 6 | 6 ≤ PFI < 12 | 12 ≤ PFI < 24 | 24 ≤ PFI | |
ORR (%) | 25 | 38 | 62 | 65 |
mPFS (95%CI) (months) | 3.2 (2.3–4.3) | 6.0 (4.4–7.3) | 7.8 (5.8–10.6) | 13.4 (10.2–20.0) |
4.4 (3.7–5.8) * | 10.3 (8.2–12.6) * | |||
mOS (95%CI) (months) | 11.3 (7.9–17.5) | 14.8 (11.5–19.5) | 27.8 (16.6–∞) | 43.0 (27.4–74.7) |
13.8 (10.6–18.1) ** | 40.9 (25.3–54.2) ** |
PFI | DSPR | Ovarian cancer | Endometrial cancer | |||
(months) | (months) | N | PFI < DSPR | N | PFI < DSPR | |
<12 | <12 | 16 | 1 | 34 | 14 | |
12≤, <24 | 0 | 0 | 8 | 8 | ||
24≤, <36 | 0 | 0 | 3 | 3 | ||
36≤ | 0 | 0 (6%) | 3 | 3 | (58%) | |
<12 | 40 | 3 | 25 | 0 | ||
12≤, <24 | 12 | 0 | 13 | 5 | ||
24≤, <36 | 0 | 0 | 3 | 3 | ||
36≤ | 0 | 0 (6%) | 2 | 2 | (23%) | |
24≤, <36 | <12 | 15 | 0 | 11 | 0 | |
12≤, <24 | 11 | 0 | 5 | 0 | ||
24≤, <36 | 1 | 0 | 3 | 1 | ||
36≤ | 0 | 0 (0%) | 0 | 0 | (5%) | |
36≤ | <12 | 6 | 0 | 9 | 0 | |
12≤, <24 | 8 | 0 | 5 | 0 | ||
24≤, <36 | 5 | 0 | 3 | 0 | ||
36≤ | 3 | 0 (0%) | 3 | 1 | (5%) | |
Total | 117 | 4 (3%) | 130 | 40 | (31%) |
Study | NRG GY-018 | RUBY [30,31] | AtTEnd [32] | DUO-E [29] | LEAP-001[34] | |||
KN868 [28] | ||||||||
Drugs | TC | TC | TC | TC | TC/Olaparib | Lenvatinib | ||
Pembrolizumab | Dostarlimab | Atezolizumab | Durvalumab | Durvalumab | Pembrolizumab | |||
N | 819 | 494 | 550 | 718 | 842 | |||
Eligibility | stage | III/IV | III/IV | III/IV | III/IV | III/IV | ||
PFI | ≥12 m | ≥6 m | ≥6 m | ≥12 m | ≥6 m | |||
carcinosarcoma | 0% | 10% | 0% | 7% | 0% | |||
non-endometrioid | 20% | 45% | 36% | 41% | 33% | |||
Duration | 14 cycles | 3 years | until PD | until PD | until PD | |||
Primary endpoint | PFS | PFS, OS | PFS, OS | PFS | PFS, OS | |||
PFS | overall | HR | 0.64 | 0.74 | 0.71 | 0.55 | 0.91 | |
(95%CI) | (0.51–0.80) | (0.61–0.91) | (0.57–0.89) | (0.43–0.69) | (0.76–1.09) | |||
dMMR | HR | 0.45 | 0.28 | 0.36 | 0.42 | 0.41 | 0.61 | |
(95%CI) | (0.27–0.73) | (0.16–0.50) | (0.23–0.57) | (0.22–0.80) | (0.21–0.75) | (0.40–0.92) | ||
pMMR | HR | 0.64 | 0.76 | 0.92 | 0.77 | 0.57 | 0.99 | |
(95%CI) | (0.49–0.85) | (0.59–0.98) | (0.73–1.16) | (0.80–0.97) | (0.44–0.73) | (0.82–1.21) | ||
overall | HR | 0.69 | 0.82 | 0.77 | 0.59 | 0.93 | ||
OS | (95%CI) | (0.54–0.89) | (0.63–1.07) | (0.56–1.07) | (0.42–0.83) | (0.77–1.12) | ||
dMMR | HR | 0.55 | 0.32 | 0.41 | 0.34 | 0.28 | 0.57 | |
(95%CI) | (0.25–1.19) | (0.17–0.63) | (0.22–0.76) | (0.13–0.79) | (0.10–0.68) | (0.36–0.91) | ||
pMMR | HR | 0.79 | 0.79 | 1.00 | 0.91 | 0.69 | 1.02 | |
(95%CI) | (0.53–1.17) | (0.60–1.04) | (0.74–1.35) | (0.64–1.30) | (0.47–1.00) | (0.83–1.26) | ||
Previous chemotherapy N | 162 | NR | 129 | 156 | 119 | |||
overall | HR | 1.15 | 0.55 | 0.52 | ||||
PFS | (95%CI) | (0.74–1.79) | (0.35–0.86) | (0.33–0.82) | ||||
pMMR | HR | 0.80 | 0.68 | 1.15 | 0.59 | 0.60 | ||
(95%CI) | (1.50–1.27) | (0.47–0.97) | (0.73–1.80) | (0.37–0.94) | (0.37–0.97) | |||
overall | HR | 0.64 | ||||||
OS | (95%CI) | (0.40–1.03) | ||||||
pMMR | HR | 0.67 | ||||||
(95%CI) | (0.41–1.11) |
PFI | |||
<6 m | 6 m≤, >12 m | 12 m≤ | |
dMMR | LEN + PEM | LEN + PEM or TC + ICI | TC + ICI |
pMMR | LEN + PEM | LEN + PEM or TC + ICI | TC + ICI or TC |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nagao, S.; Fujikawa, A.; Imatani, R.; Tani, Y.; Matsuoka, H.; Ida, N.; Haraga, J.; Ogawa, C.; Nakamura, K.; Masuyama, H. The Concept of “Platinum Sensitivity” in Endometrial Cancer. Cancers 2025, 17, 2557. https://doi.org/10.3390/cancers17152557
Nagao S, Fujikawa A, Imatani R, Tani Y, Matsuoka H, Ida N, Haraga J, Ogawa C, Nakamura K, Masuyama H. The Concept of “Platinum Sensitivity” in Endometrial Cancer. Cancers. 2025; 17(15):2557. https://doi.org/10.3390/cancers17152557
Chicago/Turabian StyleNagao, Shoji, Atsushi Fujikawa, Ryoko Imatani, Yoshinori Tani, Hirofumi Matsuoka, Naoyuki Ida, Junko Haraga, Chikako Ogawa, Keiichiro Nakamura, and Hisashi Masuyama. 2025. "The Concept of “Platinum Sensitivity” in Endometrial Cancer" Cancers 17, no. 15: 2557. https://doi.org/10.3390/cancers17152557
APA StyleNagao, S., Fujikawa, A., Imatani, R., Tani, Y., Matsuoka, H., Ida, N., Haraga, J., Ogawa, C., Nakamura, K., & Masuyama, H. (2025). The Concept of “Platinum Sensitivity” in Endometrial Cancer. Cancers, 17(15), 2557. https://doi.org/10.3390/cancers17152557